Identification

Name
Propericiazine
Accession Number
DB01608
Type
Small Molecule
Groups
Approved, Investigational
Description

Propericiazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.

Structure
Thumb
Synonyms
  • 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile
  • 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine
  • 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine
  • Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine
  • Periciazina
  • Periciazine
  • Periciazinum
  • Pericyazine
  • Piperocyanomazine
  • Propericiazine
External IDs
RP 8909 / RP-8909 / SKF 20716 / SKF-20716
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neuleptil 10mg CapsulesCapsule10 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Neuleptil 20mg CapsulesCapsule20 mgOralErfa Canada 2012 Inc1976-12-31Not applicableCanada
Neuleptil 5mg CapsulesCapsule5 mgOralErfa Canada 2012 Inc1969-12-31Not applicableCanada
Neuleptil Gouttes 10mg/mlSolution / drops10 mgOralErfa Canada 2012 Inc1976-12-31Not applicableCanada
International/Other Brands
Neulactil / Neuleptil
Categories
UNII
3405M6FD73
CAS number
2622-26-6
Weight
Average: 365.492
Monoisotopic: 365.156183063
Chemical Formula
C21H23N3OS
InChI Key
LUALIOATIOESLM-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
IUPAC Name
10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile
SMILES
OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1

Pharmacology

Indication

For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness.

Associated Conditions
Pharmacodynamics

Pericyazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects, and an action on the extrapyramidal system.

Mechanism of action

Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade of the alpha adrenergic receptors as well as antagonism of the D(1) dopamine receptor.

TargetActionsOrganism
AD(1A) dopamine receptor
antagonist
Human
AAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAndrogen receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

In milder cases of phenothiazine overdosage the patient may be agitated, delirious and confused. Frequently he is lethargic or in a comatose state. Twitching, dystonic movements or convulsions may be present and hypotension, cardiovascular collapse, arrhythmias and hypothermia might be observed.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePropericiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetaminePropericiazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetaminePropericiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePropericiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetaminePropericiazine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Propericiazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Propericiazine.Approved, Vet Approved
AdrafinilPropericiazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatinePropericiazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Propericiazine is combined with Alaproclate.Experimental
AlfentanilPropericiazine may increase the hypotensive activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Propericiazine.Approved, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Propericiazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolPropericiazine may increase the hypotensive activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodinePropericiazine may increase the hypotensive activities of Alphaprodine.Illicit
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Amantadine.Approved
AmibegronPropericiazine may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
AmisulpridePropericiazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazPropericiazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Propericiazine.Approved
AmlodipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Propericiazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the antihypertensive activities of Propericiazine.Approved
AmphetaminePropericiazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Propericiazine is combined with Amrinone.Approved
AnisodaminePropericiazine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidinePropericiazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Aranidipine.Approved, Investigational
ArbutaminePropericiazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolPropericiazine may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Propericiazine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Propericiazine.Investigational
ArtemetherThe serum concentration of Propericiazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Propericiazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Propericiazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Propericiazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Propericiazine can be increased when it is combined with Artesunate.Approved, Investigational
AsenapineAsenapine may increase the antihypertensive activities of Propericiazine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
AtovaquoneThe serum concentration of Propericiazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Propericiazine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Propericiazine is combined with Azimilide.Investigational
BambuterolPropericiazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Propericiazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Benidipine.Approved, Investigational
BenzphetaminePropericiazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BepridilThe risk or severity of hypotension can be increased when Propericiazine is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Propericiazine.Approved
BezitramidePropericiazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Propericiazine is combined with Bioallethrin.Approved, Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
BitolterolPropericiazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
BrexpiprazolePropericiazine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidinePropericiazine may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the antihypertensive activities of Propericiazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Propericiazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Propericiazine.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
BuprenorphinePropericiazine may increase the hypotensive activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Propericiazine.Approved, Investigational
ButorphanolPropericiazine may increase the hypotensive activities of Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Propericiazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Propericiazine is combined with Carboxyamidotriazole.Investigational
CarfentanilPropericiazine may increase the hypotensive activities of Carfentanil.Illicit, Investigational, Vet Approved
CaroverineThe risk or severity of hypotension can be increased when Propericiazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Propericiazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
ChloroquineThe serum concentration of Propericiazine can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenterminePropericiazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Propericiazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazineChlorpromazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational, Vet Approved
CilnidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Propericiazine is combined with Cinnarizine.Approved, Investigational
CirazolinePropericiazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Propericiazine is combined with Citalopram.Approved
ClenbuterolPropericiazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Clevidipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidinePropericiazine may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
ClozapineClozapine may increase the antihypertensive activities of Propericiazine.Approved
CodeinePropericiazine may increase the hypotensive activities of Codeine.Approved, Illicit
CyclandelateThe risk or severity of hypotension can be increased when Propericiazine is combined with Cyclandelate.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.Approved
Cycloguanil embonateThe serum concentration of Propericiazine can be increased when it is combined with Cycloguanil embonate.Experimental
DapiprazoleDapiprazole may increase the antihypertensive activities of Propericiazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Propericiazine.Investigational
DapsoneThe serum concentration of Propericiazine can be increased when it is combined with Dapsone.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Darodipine.Experimental
DesipramineDesipramine may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Propericiazine.Approved, Investigational
DetomidinePropericiazine may decrease the vasoconstricting activities of Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Deutetrabenazine.Approved, Investigational
DexmedetomidinePropericiazine may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetaminePropericiazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Propericiazine.Approved
DextromoramidePropericiazine may increase the hypotensive activities of Dextromoramide.Experimental, Illicit
DextropropoxyphenePropericiazine may increase the hypotensive activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocinePropericiazine may increase the hypotensive activities of Dezocine.Approved, Investigational
DiethylpropionPropericiazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydrocodeinePropericiazine may increase the hypotensive activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Propericiazine.Approved, Investigational
DihydroetorphinePropericiazine may increase the hypotensive activities of Dihydroetorphine.Experimental, Illicit
DihydromorphinePropericiazine may increase the hypotensive activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of hypotension can be increased when Propericiazine is combined with Diltiazem.Approved, Investigational
DiphenoxylatePropericiazine may increase the hypotensive activities of Diphenoxylate.Approved, Illicit
DipivefrinPropericiazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Propericiazine.Approved
DL-MethylephedrinePropericiazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutaminePropericiazine may decrease the vasoconstricting activities of Dobutamine.Approved
DopexaminePropericiazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Propericiazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Propericiazine.Approved
DoxepinDoxepin may increase the antihypertensive activities of Propericiazine.Approved, Investigational
DoxofyllinePropericiazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Propericiazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEPropericiazine may increase the hypotensive activities of DPDPE.Experimental
DronedaroneDronedarone may increase the antihypertensive activities of Propericiazine.Approved
DroperidolDroperidol may increase the antihypertensive activities of Propericiazine.Approved, Vet Approved
DroxidopaPropericiazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Propericiazine.Approved
EfonidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Propericiazine.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Propericiazine is combined with Eperisone.Approved, Investigational
EphedraPropericiazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrinePropericiazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastinePropericiazine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrinePropericiazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propericiazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Propericiazine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
EscitalopramEscitalopram may increase the antihypertensive activities of Propericiazine.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
EtafedrinePropericiazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Propericiazine is combined with Ethosuximide.Approved
EthylmorphinePropericiazine may increase the hypotensive activities of Ethylmorphine.Approved, Illicit
EtilefrinePropericiazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidatePropericiazine may decrease the vasoconstricting activities of Etomidate.Approved
EtorphinePropericiazine may increase the hypotensive activities of Etorphine.Illicit, Vet Approved
FelodipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Propericiazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolPropericiazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylPropericiazine may increase the hypotensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fish oilThe risk or severity of hypotension can be increased when Propericiazine is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Propericiazine is combined with Flunarizine.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Propericiazine.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Propericiazine is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Fluvoxamine.Approved, Investigational
FormoterolPropericiazine may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Propericiazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Propericiazine.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Propericiazine is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Propericiazine is combined with Gallopamil.Investigational
GepefrinePropericiazine may decrease the stimulatory activities of Gepefrine.Experimental
GuanabenzPropericiazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacinePropericiazine may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HalofantrineThe serum concentration of Propericiazine can be increased when it is combined with Halofantrine.Approved
HeroinPropericiazine may increase the hypotensive activities of Heroin.Approved, Illicit, Investigational
HexoprenalinePropericiazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePropericiazine may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocodonePropericiazine may increase the hypotensive activities of Hydrocodone.Approved, Illicit
HydromorphonePropericiazine may increase the hypotensive activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetaminePropericiazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Propericiazine can be increased when it is combined with Hydroxychloroquine.Approved
IloperidoneIloperidone may increase the antihypertensive activities of Propericiazine.Approved
ImipramineImipramine may increase the antihypertensive activities of Propericiazine.Approved
IndacaterolPropericiazine may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Indalpine.Investigational, Withdrawn
IndenololIndenolol may increase the orthostatic hypotensive activities of Propericiazine.Withdrawn
IndoraminIndoramin may increase the antihypertensive activities of Propericiazine.Withdrawn
Iofetamine I-123Propericiazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Propericiazine.Approved
IsoetarinePropericiazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsometheptenePropericiazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalinePropericiazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprinePropericiazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Isradipine.Approved, Investigational
KetobemidonePropericiazine may increase the hypotensive activities of Ketobemidone.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Propericiazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Propericiazine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Propericiazine.Investigational
LercanidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Propericiazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
LevobunololPropericiazine may increase the hypotensive activities of Levobunolol.Approved
LevodopaThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetatePropericiazine may increase the hypotensive activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Propericiazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolPropericiazine may increase the hypotensive activities of Levorphanol.Approved
LevosalbutamolPropericiazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Propericiazine.Approved, Investigational
LisdexamfetaminePropericiazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Propericiazine.Approved
LofentanilPropericiazine may increase the hypotensive activities of Lofentanil.Illicit
LofexidinePropericiazine may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Propericiazine is combined with Loperamide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Propericiazine.Approved
LumefantrineThe serum concentration of Propericiazine can be increased when it is combined with Lumefantrine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Propericiazine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propericiazine.Approved, Investigational
MedetomidinePropericiazine may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Propericiazine can be increased when it is combined with Mefloquine.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Propericiazine is combined with Menthol.Approved
MephedronePropericiazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePropericiazine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
MeptazinolPropericiazine may increase the hypotensive activities of Meptazinol.Experimental
MequitazinePropericiazine may increase the arrhythmogenic activities of Mequitazine.Approved
MetaraminolPropericiazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadonePropericiazine may increase the hypotensive activities of Methadone.Approved
Methadyl AcetatePropericiazine may increase the hypotensive activities of Methadyl Acetate.Approved, Illicit
MethamphetaminePropericiazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethotrimeprazineMethotrimeprazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
MethoxaminePropericiazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenaminePropericiazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Propericiazine is combined with Methsuximide.Approved
MethyldopaPropericiazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Propericiazine is combined with Methylphenidate.Approved, Investigational
MetipranololPropericiazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Propericiazine.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Propericiazine.Approved
MibefradilThe risk or severity of hypotension can be increased when Propericiazine is combined with Mibefradil.Investigational, Withdrawn
MidodrinePropericiazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetaminePropericiazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Propericiazine is combined with Milnacipran.Approved, Investigational
MirabegronPropericiazine may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Propericiazine.Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propericiazine.Approved
MizoribineThe serum concentration of Propericiazine can be increased when it is combined with Mizoribine.Investigational
MMDAPropericiazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Propericiazine.Approved, Investigational
MorphinePropericiazine may increase the hypotensive activities of Morphine.Approved, Investigational
MoxonidinePropericiazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Propericiazine is combined with Naftopidil.Investigational
NalbuphinePropericiazine may increase the hypotensive activities of Nalbuphine.Approved
NaphazolinePropericiazine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Propericiazine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
NefazodoneNefazodone may increase the antihypertensive activities of Propericiazine.Approved, Withdrawn
NicardipineNicardipine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Propericiazine.Approved, Investigational
NicomorphinePropericiazine may increase the hypotensive activities of Nicomorphine.Experimental
NifedipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nifedipine.Approved
NiguldipineNiguldipine may increase the antihypertensive activities of Propericiazine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Propericiazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nitrendipine.Approved, Investigational
NorepinephrinePropericiazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrinePropericiazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NormethadonePropericiazine may increase the hypotensive activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Propericiazine.Approved
NylidrinPropericiazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopaminePropericiazine may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineOlanzapine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
OlodaterolPropericiazine may decrease the vasoconstricting activities of Olodaterol.Approved
OpiumPropericiazine may increase the hypotensive activities of Opium.Approved, Illicit
OrciprenalinePropericiazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Propericiazine is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
OxycodonePropericiazine may increase the hypotensive activities of Oxycodone.Approved, Illicit, Investigational
OxyfedrinePropericiazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolinePropericiazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphonePropericiazine may increase the hypotensive activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the antihypertensive activities of Propericiazine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PentazocinePropericiazine may increase the hypotensive activities of Pentazocine.Approved, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Propericiazine.Approved, Investigational
PergolidePropericiazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PethidinePropericiazine may increase the hypotensive activities of Pethidine.Approved
PhenazocinePropericiazine may increase the hypotensive activities of Phenazocine.Experimental
PhendimetrazinePropericiazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Propericiazine.Approved
PhenoperidinePropericiazine may increase the hypotensive activities of Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Propericiazine.Approved
PhenterminePropericiazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the antihypertensive activities of Propericiazine.Approved
PhenylephrinePropericiazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePropericiazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinaveriumThe risk or severity of hypotension can be increased when Propericiazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PiperaquineThe serum concentration of Propericiazine can be increased when it is combined with Piperaquine.Approved, Investigational
PirbuterolPropericiazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Piribedil.Investigational
PiritramidePropericiazine may increase the hypotensive activities of Piritramide.Approved, Investigational
PizotifenPizotifen may increase the antihypertensive activities of Propericiazine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Propericiazine.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
PramipexoleThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Propericiazine.Approved
PrenalterolPropericiazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Propericiazine is combined with Prenylamine.Withdrawn
PrimaquineThe serum concentration of Propericiazine can be increased when it is combined with Primaquine.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Propericiazine.Approved, Investigational
ProcaterolPropericiazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProguanilThe serum concentration of Propericiazine can be increased when it is combined with Proguanil.Approved
PromazinePromazine may increase the antihypertensive activities of Propericiazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Propericiazine.Approved, Investigational
PropafenonePropafenone may increase the orthostatic hypotensive activities of Propericiazine.Approved
PropiomazinePropiomazine may increase the antihypertensive activities of Propericiazine.Approved
PropiverinePropiverine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropranololPropranolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
ProtokylolPropericiazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.Approved
PseudoephedrinePropericiazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Propericiazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Propericiazine can be increased when it is combined with Pyronaridine.Investigational
QuetiapineQuetiapine may increase the antihypertensive activities of Propericiazine.Approved
QuinacrineThe serum concentration of Propericiazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Propericiazine.Approved, Investigational
QuinidineQuinidine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
QuinineThe serum concentration of Propericiazine can be increased when it is combined with Quinine.Approved
RacepinephrinePropericiazine may increase the antihypertensive activities of Racepinephrine.Approved
RactopaminePropericiazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Propericiazine can be increased when it is combined with Radicicol.Experimental
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Propericiazine.Approved
RemifentanilPropericiazine may increase the hypotensive activities of Remifentanil.Approved
ReproterolPropericiazine may decrease the vasoconstricting activities of Reproterol.Investigational
RilmenidinePropericiazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RimiterolPropericiazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
RitobegronPropericiazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrinePropericiazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Propericiazine.Approved
RomifidinePropericiazine may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Ropinirole.Approved, Investigational
RotigotineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Rotigotine.Approved
SalbutamolPropericiazine may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolPropericiazine may decrease the vasoconstricting activities of Salmeterol.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Propericiazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Propericiazine is combined with Seletracetam.Investigational
SertralineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Propericiazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Propericiazine.Approved
SinefunginThe serum concentration of Propericiazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolabegronPropericiazine may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Propericiazine.Approved
SufentanilPropericiazine may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Propericiazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Propericiazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpiridePropericiazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Propericiazine.Approved, Investigational
SynephrinePropericiazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Propericiazine.Approved, Investigational
TafenoquineThe serum concentration of Propericiazine can be increased when it is combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Propericiazine.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Propericiazine.Approved, Investigational
TapentadolPropericiazine may increase the hypotensive activities of Tapentadol.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Propericiazine.Approved
TerazosinTerazosin may increase the antihypertensive activities of Propericiazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Propericiazine.Approved
TerodilineThe risk or severity of hypotension can be increased when Propericiazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Propericiazine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Propericiazine.Approved, Investigational
TetrahydropalmatineThe risk or severity of hypotension can be increased when Propericiazine is combined with Tetrahydropalmatine.Investigational
TetryzolinePropericiazine may decrease the vasoconstricting activities of Tetryzoline.Approved
TheophyllineTheophylline may increase the hypotensive activities of Propericiazine.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Propericiazine is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the antihypertensive activities of Propericiazine.Approved
ThioridazineThioridazine may increase the antihypertensive activities of Propericiazine.Approved, Withdrawn
TilidinePropericiazine may increase the hypotensive activities of Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Propericiazine.Approved
TizanidinePropericiazine may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Propericiazine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Propericiazine is combined with Tolfenamic Acid.Approved, Investigational
TramadolPropericiazine may increase the hypotensive activities of Tramadol.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Propericiazine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
TretoquinolPropericiazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
TrimazosinTrimazosin may increase the antihypertensive activities of Propericiazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Propericiazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Propericiazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Propericiazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Propericiazine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolPropericiazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Propericiazine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Propericiazine.Investigational
VardenafilVardenafil may increase the hypotensive activities of Propericiazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Propericiazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Propericiazine.Approved
VerapamilVerapamil may increase the antihypertensive activities of Propericiazine.Approved
VilanterolPropericiazine may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Propericiazine.Approved
VinpocetineThe risk or severity of hypotension can be increased when Propericiazine is combined with Vinpocetine.Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propericiazine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Propericiazine is combined with WIN 55212-2.Experimental
XamoterolPropericiazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazinePropericiazine may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolinePropericiazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Propericiazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the antihypertensive activities of Propericiazine.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Propericiazine.Approved, Investigational
ZonisamideThe risk or severity of hypotension can be increased when Propericiazine is combined with Zonisamide.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the antihypertensive activities of Propericiazine.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015546
KEGG Drug
D01485
PubChem Compound
4747
PubChem Substance
46505085
ChemSpider
4585
BindingDB
50346422
ChEBI
31981
ChEMBL
CHEMBL251940
Therapeutic Targets Database
DAP000413
PharmGKB
PA164781043
Wikipedia
Propericiazine
ATC Codes
N05AC01 — Periciazine
AHFS Codes
  • 28:16.08.24 — Phenothiazines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentPsychosis Nos/Other1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral20 mg
CapsuleOral5 mg
Solution / dropsOral10 mg
Prices
Unit descriptionCostUnit
Neuleptil 20 mg Capsule0.52USD capsule
Neuleptil 10 mg/ml Drops0.41USD ml
Neuleptil 10 mg Capsule0.34USD capsule
Neuleptil 5 mg Capsule0.21USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)116-117 °CPhysProp
water solubility38 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
logS-3.98ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.059 mg/mLALOGPS
logP3.78ALOGPS
logP3.11ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)15.18ChemAxon
pKa (Strongest Basic)8.37ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.5 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity108.4 m3·mol-1ChemAxon
Polarizability40.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.9691
Caco-2 permeable+0.5608
P-glycoprotein substrateSubstrate0.6582
P-glycoprotein inhibitor IInhibitor0.8072
P-glycoprotein inhibitor IIInhibitor0.6046
Renal organic cation transporterInhibitor0.6545
CYP450 2C9 substrateNon-substrate0.7657
CYP450 2D6 substrateSubstrate0.6233
CYP450 3A4 substrateNon-substrate0.6064
CYP450 1A2 substrateInhibitor0.6843
CYP450 2C9 inhibitorNon-inhibitor0.8852
CYP450 2D6 inhibitorInhibitor0.6558
CYP450 2C19 inhibitorNon-inhibitor0.8539
CYP450 3A4 inhibitorNon-inhibitor0.8952
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7203
Ames testNon AMES toxic0.6802
CarcinogenicityNon-carcinogens0.9537
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7341
hERG inhibition (predictor II)Inhibitor0.6604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03xu-7932000000-163720fa7ee8e5adf313
GC-MS Spectrum - EI-BGC-MSsplash10-03di-4931000000-bc6eaf361b17af48a30f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Piperidines / Benzenoids / 1,4-thiazines / Trialkylamines / Secondary alcohols / Nitriles / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Piperidine / Benzenoid / Secondary alcohol / Tertiary aliphatic amine
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, nitrile, hydroxypiperidine (CHEBI:31981)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [PubMed:7918347]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [PubMed:6149771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [PubMed:17606915]

Drug created on August 29, 2007 12:52 / Updated on June 19, 2018 10:50